Further US Lawsuit Claims Price-Fixing Conspiracy

Teva, along with Mylan, Pfizer, Sandoz and 16 other generics manufacturers, have found themselves in the spotlight after a further multi-state US lawsuit has accused them of participating in a price-fixing conspiracy.

Glasses
The latest lawsuit once again focuses on an alleged pricing conspiracy • Source: Shutterstock

A second multi-state lawsuit has been filed in the US as part of an ongoing and expanding investigation into generic drug pricing.

Teva, along with Mylan, Pfizer, Sandoz and 16 other generics manufacturers, have been named in a...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Drug Pricing

GB-Policy&Regulation (Premium-1): Lead Exposure Is Still a Problem for Kids, and the Pandemic Has Made It Worse

 
• By 

Video provides a powerful way to help you prove your point. When you click Online Video, you can paste in the embed code for the video you want to add. You can also type a keyword to search online for the video that best fits your document.

Polpharma And MSN Labs Team Up On Distribution

 
• By 

Polpharma has struck a deal with MSN Laboratories that will see the Polish generics player distribute the Indian firm’s hospital portfolio in Poland.

FDA Approves Accord’s Higher Strength Herceptin Biosimilar

 
• By 

Following the FDA’s approval of A 150mg version of Accord’ Herceptin biosimilar, the US agency has now greenlit a higher 400mg strength version of the rival.

‘It’s Not Going To Be An Easy Market’ – Hikma Talks Strategy For US Biosimilars

 
• By 

During Hikma’s first-half results call, the company delved into details of its strategic goals for biosimilars, small-molecule generics, injectables, GLP-1s and more.

More from Policy & Regulation

For Generics, A Victory Lap – And A Warning – On Drug Shortages

Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

GB-Policy&Regulation-Free: Article with different widgets

Emerging CRISPR innovations, shifting regulatory landscapes, and rising partnerships are accelerating a paradigm shift in biotech pipelines

Overseas API Manufacturing Identified As Key Vulnerability In US Supply Chain

After US President Joe Biden launched a review of the country’s API supply chain, the task force has reported back with key vulnerabilities that contribute to drug shortages and supply risks during a global public health emergency. According to the report, the lack of geographic diversity and dependence on foreign nations and anti-competitive actions by foreign nations are key areas of concern.